TrialEmerging microbes & infections2025
Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.
Karin Kosulin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papertrialcites it